SGLT-2 inhibitors and nephrolithiasis risk: a meta-analysis.
Mehmet KanbayCrischentian BrinzaSidar CopurOzge SekreterAlexandru BurlacuKatherine R TuttleEllen BurgessAdrian CovicPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
We have demonstrated a lower risk of nephrolithiasis risk with SGLT-2 inhibitor therapy compared to placebo or active control. Potential underlying mechanisms include osmotic diuresis leading to a reduction in the concentration of lithogenic substances, anti-inflammatory and anti-fibrotic effects, and an increase in urine pH. There is a clear need for future large-scale randomized clinical trials evaluating such associations for better understanding.